Diabetes Monit 2001;2(4):306-316.
2 형 당뇨병에서 Repaglinide 의 유용성에 대한 연구
박철영, 김영설, 이현철, 장학철
Comparison of Repaglinide and Gliclazide for the Treatment of Type 2 Diabetes
Cheol Young Park, Young Seol Kim, Hyun Chul Lee, Hak Chul Jang
Abstract
Background
This study was designed to compare the efficacy and safety of repaglinide with gliclazide in a 12-week open-labelled, randomized, parallel group, multi-center study of outpatients with type 2 diabetes. Methods: A total of 182 patients were screened. 154 patients were randomized in a 1:1 ratio of repaglinide (78 patients) and gliclazide (76 patients). Two randomized patients withdrew from the trial prior to receive any trial medication. At the end of trial, 127 patients completed. The study protocol included a screening visit to assess patient eligibility; a washout period of 2 weeks, a titration period of 4 weeks, and a subsequent 8 week maintenance period. Repaglinide was administered preprandially with the three main meals, and gliclazide was taken according to the product labeling. Results: After 12 weeks treatment, both repaglinide and gliclazide resulted in significant reductions in HbA1c (p<0.001; both treatment groups) and fasting blood glucose (FBG) values (p<0.001; both treatment groups). Significant reductions in postprandial blood glucose (PPBG) values were found in the repaglinide group at 60 minutes (p<0.05) and at 90 minutes (p<0.05). However, no significant treatment differences in HbA1c, FBG, or PPBG were observed. Both number of patients and frequency of reported hypoglycemic events appeared to be lower in the repaglinide group than in the gliclazide group (not significant). Conclusion: Overall, the results showed that repaglinide is well-tolerated and equally effective in controlling HbA1c, FBG and PPBG as gliclazide
Key Words: Repaglinide , NovoNorm(R) , Gliclazide , Type 2 diabetes


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer